 |
| Colin Shannon |
27 May 2014, RALEIGH, N.C. – PRA, a leading clinical research organization, today announced it has completed its 20th first in human trial with biologics. The milestone is the culmination of 600 subjects enrolled in over eight years of first in human biologics trials, including directly into patient experience.
Biologics represent an important class of agents with an increasing share in modern medicine, as a response to improved understanding of molecular and genetic bases of disease. With the increased number of biological compounds being developed, PRA is poised to provide its clients with a high-end Phase I unit capable of safely and effectively evaluating compounds.
“At PRA, we are extremely proud of our continued, successful delivery of clinical development services in this exciting and important field of medicine,” said Ewoud-Jan van Hoogdalem, vice president, Global Scientific Affairs, Early Development Services. “With our focus on science, we are keen to work with our clients to design and execute programs that provide the best answers to the development questions for the product. All of our eight ‘science embedded’ Phase I units in the U.S. and Europe provide an excellent starting point for these programs.”
#ColinShannon #MrColinShannon #PRAhealthsciences @MrColinShannon
www.ColinShannon.info | www.ColinShannon.today | www.ColinShannon.pictures | www.PRAHS.com
No comments:
Post a Comment